1. Home
  2. WT vs ADPT Comparison

WT vs ADPT Comparison

Compare WT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WisdomTree Inc.

WT

WisdomTree Inc.

HOLD

Current Price

$19.04

Market Cap

2.6B

Sector

Finance

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$13.66

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WT
ADPT
Founded
1985
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
WT
ADPT
Price
$19.04
$13.66
Analyst Decision
Hold
Strong Buy
Analyst Count
3
9
Target Price
$17.67
$17.78
AVG Volume (30 Days)
3.0M
1.7M
Earning Date
05-01-2026
05-05-2026
Dividend Yield
0.74%
N/A
EPS Growth
127.27
63.89
EPS
N/A
N/A
Revenue
$493,753,000.00
$276,976,000.00
Revenue This Year
$35.04
$3.98
Revenue Next Year
$8.68
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
15.43
54.77
52 Week Low
$9.24
$8.50
52 Week High
$19.29
$20.76

Technical Indicators

Market Signals
Indicator
WT
ADPT
Relative Strength Index (RSI) 65.87 46.90
Support Level $15.69 $12.22
Resistance Level N/A $15.38
Average True Range (ATR) 0.80 0.81
MACD 0.20 0.03
Stochastic Oscillator 94.19 37.79

Price Performance

Historical Comparison
WT
ADPT

About WT WisdomTree Inc.

WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: